

Ricky w Johnstone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/982939/ricky-w-johnstone-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

251
papers

25,431
citations

78
h-index

156
g-index

270
ext. papers

28,285
ext. citations

11.3
avg, IF

7.21
L-index

#	Paper	IF	Citations
251	Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML.. <i>Cancer Discovery</i> , 2022 ,	24.4	1
250	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.. <i>EMBO Molecular Medicine</i> , 2022 , e15203	12	0
249	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. <i>Haematologica</i> , 2021 , 106, 2013-2017	6.6	1
248	Targeting transcription cycles in cancer. <i>Nature Reviews Cancer</i> , 2021 ,	31.3	9
247	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4338-4352	12.9	0
246	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021 , 81, 2183-2200.e13	17.6	12
245	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021 , 11, 2582-2601	24.4	12
244	Antigen-driven EGR2 expression is required for exhausted CD8 T cell stability and maintenance. <i>Nature Communications</i> , 2021 , 12, 2782	17.4	4
243	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021 , 184, 3143-3162.e32	56.2	20
242	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. <i>Blood</i> , 2021 , 137, 2947-2957	2.2	4
241	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 1582-1599	24.4	11
240	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. <i>Science Advances</i> , 2021 , 7,	14.3	13
239	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6222-6234	12.9	4
238	Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 502-514	4	8
237	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020 , 6,	14.3	35
236	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. <i>Journal of Immunology</i> , 2020 , 204, 2308-2315	5.3	12
235	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. <i>Leukemia</i> , 2020 , 34, 1646-1657	10.7	31

234	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020 , 26, 6535-6549	12.9	15
233	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020 , 33, 108290	10.6	2
232	Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. <i>Leukemia</i> , 2020 , 34, 3388-3392	10.7	12
231	MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. <i>Blood Advances</i> , 2020 , 4, 4918-4923	7.8	2
230	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020 , 28, 2379-2393	11.7	19
229	Targeting the epigenetic regulation of antitumour immunity. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 776-800	64.1	81
228	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019 , 28, 2784-2794.e56	11.6	46
227	Joseph F. Sambrook (1939-2019). <i>Nature Structural and Molecular Biology</i> , 2019 , 26, 846-847	17.6	
226	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. <i>Nature Communications</i> , 2019 , 10, 1347	17.4	25
225	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2019 , 25, 258-272.e9	18	32
224	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019 , 7, 183-192	12.5	33
223	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. <i>Cell Death and Disease</i> , 2018 , 9, 442	9.8	12
222	A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. <i>Methods in Molecular Biology</i> , 2018 , 1725, 201-227	1.4	3
221	Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018 , 32, 237-241	10.7	17
220	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. <i>Nature</i> , 2018 , 560, 253-257	50.4	103
219	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. <i>Genes and Development</i> , 2018 , 32, 849-864	12.6	17
218	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018 , 9, 5341	17.4	227
217	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018 , 3,	28	119

216	Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. <i>Cell Death and Differentiation</i> , 2017 , 24, 961-970	12.7	45
215	HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. <i>Leukemia</i> , 2017 , 31, 995-997	10.7	16
214	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017 , 17, 160-183	13.3	54
213	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. <i>Leukemia</i> , 2017 , 31, 1466-1470	10.7	19
212	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 Tumors. <i>Cancer Research</i> , 2017 , 77, 2594-2606	10.1	15
211	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017 , 18, 2162-2174	10.6	170
210	Genomic characterisation of EMyc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. <i>Nature Communications</i> , 2017 , 8, 14581	17.4	22
209	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017 , 129, 2882-2895	2.2	49
208	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017 , 23, 2478-2490	12.9	71
207	DOCK8 Drives Src-Dependent NK Cell Effector Function. <i>Journal of Immunology</i> , 2017 ,	5.3	12
206	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , 2017 , 58, 996-998	1.9	10
205	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 929-941	15.9	183
204	Scribble acts as an oncogene in EMyc-driven lymphoma. <i>Oncogene</i> , 2016 , 35, 1193-7	9.2	10
203	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016 , 101, e387-90	6.6	94
202	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2030-41	6.1	39
201	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016 , 538, 518-522	50.4	122
200	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. <i>Science Translational Medicine</i> , 2016 , 8, 339ra69	17.5	111
199	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. <i>Cancer Research</i> , 2016 , 76, 3965-77	10.1	23

198	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 673-81	17.6	69
197	Constitutive IFN γ signaling maintains expression of signaling intermediaries for efficient cytokine responses. <i>Jak-stat</i> , 2016 , 5, e1173804		2
196	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016 , 76, 1158-69	10.1	73
195	A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. <i>Cell Death and Differentiation</i> , 2016 , 23, 1209-18	12.7	10
194	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016 , 29, 145-53	24.3	71
193	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. <i>Cell Reports</i> , 2016 , 14, 1858-66	10.6	25
192	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discovery</i> , 2016 , 6, 59-70	24.4	73
191	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016 , 7, 49800-49818	3.3	62
190	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. <i>Oncotarget</i> , 2016 , 7, 34582-98	3.3	8
189	Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity. <i>FEBS Journal</i> , 2016 , 283, 947-61	5.7	23
188	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2016 , 30, 59-74	24.3	18
187	How do tumor cells respond to HDAC inhibition?. <i>FEBS Journal</i> , 2016 , 283, 4032-4046	5.7	81
186	In the Midst of Life-Cell Death: What Is It, What Is It Good for, and How to Study It. <i>Cold Spring Harbor Protocols</i> , 2016 , 2016,	1.2	1
185	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. <i>Oncogenesis</i> , 2016 , 5, e216	6.6	22
184	Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Aesthetic Surgery Journal</i> , 2016 , 36, 782-3	2.4	9
183	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016 , 34, 1010-1014	44.5	46
182	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. <i>International Journal of Cancer</i> , 2016 , 139, 194-204	7.5	21
181	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015 , 7, 2	7.7	8

180	Manipulation of B-cell responses with histone deacetylase inhibitors. <i>Nature Communications</i> , 2015 , 6, 6838	17.4	60
179	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015 , 525, 538-42	50.4	345
178	Letter to the Editor, "BET inhibitor JQ1 blocks inflammation and bone destruction". <i>Journal of Dental Research</i> , 2015 , 94, 229	8.1	1
177	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. <i>Blood</i> , 2015 , 126, 2392-403	2.2	38
176	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
175	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. <i>Leukemia</i> , 2015 , 29, 1437-41	10.7	90
174	A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage. <i>Cell Death and Differentiation</i> , 2014 , 21, 748-60	12.7	13
173	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. <i>Nature Medicine</i> , 2014 , 20, 283-90	50.5	68
172	From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. <i>Cancer Cell</i> , 2014 , 25, 9-11	24.3	25
171	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. <i>Blood</i> , 2014 , 123, 1341-52	2.2	82
170	The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. <i>Radiation Research</i> , 2014 , 182, 219-29	3.1	24
169	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , 2014 , 4, 423-33	24.4	180
168	The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμmyc model of B-cell lymphoma. <i>Oncogene</i> , 2014 , 33, 5415-23	9.2	40
167	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 673-91	64.1	1028
166	The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. <i>Cell Reports</i> , 2014 , 7, 1009-19	10.6	24
165	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. <i>Leukemia Research</i> , 2014 , 38, 948-54	2.7	12
164	Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. <i>Scientific Data</i> , 2014 , 1, 140017	8.2	13
163	Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. <i>Blood</i> , 2014 , 123, 725-33	2.2	46

162	Id2 represses E2A-mediated activation of IL-10 expression in T cells. <i>Blood</i> , 2014 , 123, 3420-8	2.2	18
161	New and emerging HDAC inhibitors for cancer treatment. <i>Journal of Clinical Investigation</i> , 2014 , 124, 30-9	15.9	936
160	Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2014 , 10, e1004473	7.6	358
159	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014 , 21, 297-308	3.3	8
158	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. <i>Bioinformatics</i> , 2014 , 30, 1064-1072	7.2	60
157	The anticancer effects of HDAC inhibitors require the immune system. <i>Oncolmmunology</i> , 2014 , 3, e27414	7.2	56
156	Lethal giant larvae 1 tumour suppressor activity is not conserved in models of mammalian T and B cell leukaemia. <i>PLoS ONE</i> , 2014 , 9, e87376	3.7	13
155	Modulation of antitumour immune responses by intratumoural Stat1 expression. <i>Immunology and Cell Biology</i> , 2013 , 91, 556-67	5	9
154	Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. <i>Cell Reports</i> , 2013 , 5, 1047-59	10.6	98
153	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. <i>Thrombosis Research</i> , 2013 , 131, 514-20	8.2	8
152	An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. <i>Cancer Research</i> , 2013 , 73, 7265-76	10.1	96
151	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013 , 49, 3936-44	7.5	63
150	AKT signalling is required for ribosomal RNA synthesis and progression of EEMyc B-cell lymphoma in vivo. <i>FEBS Journal</i> , 2013 , 280, 5307-16	5.7	16
149	The mTORC1 inhibitor everolimus prevents and treats EEMyc lymphoma by restoring oncogene-induced senescence. <i>Cancer Discovery</i> , 2013 , 3, 82-95	24.4	52
148	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. <i>Oncogene</i> , 2013 , 32, 4191-202	9.2	61
147	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013 , 4, e519	9.8	126
146	Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2709-21	6.1	42
145	Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2-deoxycytidine in solid tumor cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2226-36	6.1	64

144	Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. <i>Cell Death and Disease</i> , 2013 , 4, e798	9.8	29
143	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. <i>Blood</i> , 2013 , 121, 2964-74	2.2	54
142	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. <i>Blood</i> , 2013 , 121, 3459-68	2.2	95
141	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012 , 120, 822-32	2.2	45
140	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. <i>Blood</i> , 2012 , 120, 376-85	2.2	143
139	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. <i>Blood</i> , 2012 , 120, 3019-29	2.2	53
138	Oncogenes in cell survival and cell death. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012 , 4,	10.2	79
137	Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. <i>Cell Death and Disease</i> , 2012 , 3, e387	9.8	9
136	Constitutive type I interferon modulates homeostatic balance through tonic signaling. <i>Immunity</i> , 2012 , 36, 166-74	32.3	291
135	Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. <i>Immunity</i> , 2012 , 36, 561-71	32.3	352
134	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). <i>Epigenomics</i> , 2012 , 4, 571-89	4.4	35
133	Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. <i>Leukemia</i> , 2012 , 26, 1433-5	10.7	2
132	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. <i>Cancer Cell</i> , 2012 , 22, 51-65	24.3	368
131	Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death. <i>Cancer Discovery</i> , 2012 , 2, 112-4	24.4	9
130	Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. <i>Cancer Research</i> , 2012 , 72, 3163-74	10.1	208
129	Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. <i>Oncolmmunology</i> , 2012 , 1, 1629-1631	7.2	10
128	The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. <i>Oncolmmunology</i> , 2012 , 1, 377-379	7.2	12
127	Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. <i>Cell Death and Disease</i> , 2012 , 3, e344	9.8	15

126	PIDDosome-independent tumor suppression by Caspase-2. <i>Cell Death and Differentiation</i> , 2012 , 19, 1722-1727	3.7	49
125	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. <i>Cell Death and Disease</i> , 2012 , 3, e409	9.8	36
124	Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. <i>Oncogene</i> , 2012 , 31, 1661-72	9.2	106
123	Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. <i>Advances in Cancer Research</i> , 2012 , 116, 165-97	5.9	84
122	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 553-7	15.9	144
121	Promises and challenges of anticancer drugs that target the epigenome. <i>Epigenomics</i> , 2011 , 3, 547-65	4.4	19
120	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011 , 117, 3658-68	2.2	118
119	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011 , 118, 6274-83	2.2	69
118	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011 , 90, 847-9	3	13
117	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011 , 128, 2735-47	7.5	9
116	In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1440-9	6.1	66
115	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 4141-6	11.5	88
114	Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. <i>Cancer Research</i> , 2011 , 71, 3603-15	10.1	46
113	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. <i>Science Signaling</i> , 2011 , 4, ra56	8.8	104
112	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010 , 3, 2674-2688	5.2	6
111	Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms. <i>Journal of Immunology</i> , 2010 , 185, 367-75	5.3	94
110	Functional crosstalk between type I and II interferon through the regulated expression of STAT1. <i>PLoS Biology</i> , 2010 , 8, e1000361	9.7	108
109	SnapShot: Extrinsic apoptosis pathways. <i>Cell</i> , 2010 , 143, 1192, 1192.e1-2	56.2	51

108	Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence. <i>Journal of Cellular Biochemistry</i> , 2010 , 109, 103-12	4.7	11
107	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010 , 28 Suppl 1, S3-20	4.3	106
106	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. <i>Future Oncology</i> , 2009 , 5, 601-12	3.6	111
105	Perforin-mediated suppression of B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2723-8	11.5	36
104	Rational combinations using HDAC inhibitors. <i>Clinical Cancer Research</i> , 2009 , 15, 3970-7	12.9	195
103	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. <i>Cancer Letters</i> , 2009 , 280, 125-33	9.9	184
102	Epigenetics in cancer: targeting chromatin modifications. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1409-20	11.1	384
101	Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. <i>Blood</i> , 2009 , 113, 1982-91	2.2	72
100	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. <i>Blood</i> , 2009 , 114, 380-93	2.2	100
99	Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. <i>PLoS ONE</i> , 2009 , 4, e4482	3.7	44
98	The TRAIL apoptotic pathway in cancer onset, progression and therapy. <i>Nature Reviews Cancer</i> , 2008 , 8, 782-98	31.3	690
97	Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. <i>Cell Death and Differentiation</i> , 2008 , 15, 708-17	12.7	33
96	IFN γ signaling-does it mean JAK-STAT?. <i>Cytokine and Growth Factor Reviews</i> , 2008 , 19, 383-94	17.9	232
95	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 11317-22	11.5	114
94	Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. <i>Clinical Cancer Research</i> , 2008 , 14, 4500-10	12.9	257
93	Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1066-79	6.1	58
92	The role of p202 in regulating hematopoietic cell proliferation and differentiation. <i>Journal of Interferon and Cytokine Research</i> , 2008 , 28, 5-11	3.5	9
91	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16254-9	11.5	40

90	Histone deacetylase inhibitors in lymphoma and solid malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 413-32	3.5	78
89	Cloning and characterisation of Ifi206: a new murine HIN-200 family member. <i>Journal of Cellular Biochemistry</i> , 2008 , 103, 1270-82	4.7	6
88	Epigenetic Drugs 2008 , 49-71		
87	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 8071-6	11.5	185
86	Histone deacetylase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 659-78	3.9	178
85	From cancer immunosurveillance to cancer immunotherapy. <i>Immunological Reviews</i> , 2007 , 220, 82-101	11.3	70
84	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19512-7	11.5	569
83	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1439-49	3.5	35
82	A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. <i>Journal of Biological Chemistry</i> , 2007 , 282, 938-46	5.4	44
81	The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. <i>Cell</i> , 2007 , 129, 423-33	56.2	170
80	Response: Does Bid Play a Role in the DNA Damage Response?. <i>Cell</i> , 2007 , 130, 10-11	56.2	10
79	Anticancer activities of histone deacetylase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 769-84	64.1	2286
78	The HIN-200 family: more than interferon-inducible genes?. <i>Experimental Cell Research</i> , 2005 , 308, 1-17	4.2	132
77	Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 326, 417-24	3.4	36
76	Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. <i>Oncogene</i> , 2005 , 24, 8061-75	1.75	169
75	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3697-702	11.5	451
74	A central role for Bid in granzyme B-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2005 , 280, 4476-82	8.4	101
73	Histone-Deacetylase Inhibitors for the Treatment of Cancer. <i>Cell Cycle</i> , 2004 , 3, 777-786	4.7	110

72	The multidrug resistance gene <i>mdr1a</i> influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. <i>Immunology and Cell Biology</i> , 2004 , 82, 462-70	5	6
71	Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. <i>Cell Death and Differentiation</i> , 2004 , 11, 1028-37	12.7	87
70	Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. <i>Oncogene</i> , 2004 , 23, 6693-701	11	118
69	Growth Suppressors IFI-204 and IFI-205 Inhibit Primitive Hematopoietic Cell Proliferation In Vitro and in Vivo.. <i>Blood</i> , 2004 , 104, 1691-1691	2.2	
68	Histone-deacetylase inhibitors for the treatment of cancer. <i>Cell Cycle</i> , 2004 , 3, 779-88	4.7	40
67	Suberanilohydroxamic Acid. Aton Pharma. <i>IDrugs: the Investigational Drugs Journal</i> , 2004 , 7, 674-82		2
66	Expression of IFI 16 in epithelial cells and lymphoid tissues. <i>Histochemistry and Cell Biology</i> , 2003 , 119, 45-54	2.4	53
65	A role for P-glycoprotein in regulating cell growth and survival. <i>Clinical and Applied Immunology Reviews</i> , 2003 , 4, 31-47		12
64	Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. <i>Cancer Cell</i> , 2003 , 4, 13-8	24.3	425
63	Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI 16. <i>Journal of Cellular Biochemistry</i> , 2003 , 89, 80-93	4.7	22
62	A member of the Pysin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. <i>Oncogene</i> , 2003 , 22, 8931-8	9.2	102
61	Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. <i>Oncogene</i> , 2003 , 22, 4831-40	9.2	94
60	Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. <i>Molecular and Cellular Biology</i> , 2003 , 23, 6520-32	4.8	61
59	Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. <i>Cancer Research</i> , 2003 , 63, 4460-71	10.1	160
58	Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. <i>International Journal of Cancer</i> , 2002 , 99, 292-8	7.5	65
57	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 965-9	4.5	35
56	P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. <i>Cell Death and Differentiation</i> , 2002 , 9, 1266-72	12.7	71
55	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 287-99	64.1	1177

54	Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. <i>Journal of Virology</i> , 2002 , 76, 2692-702	6.6	95
53	Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. <i>Current Cancer Drug Targets</i> , 2002 , 2, 337-53	2.8	20
52	P-glycoprotein as a General Antiapoptotic Protein 2002 , 433-441		
51	Apoptosis: a link between cancer genetics and chemotherapy. <i>Cell</i> , 2002 , 108, 153-64	56.2	1883
50	Deamidation of Bcl-X(L): a new twist in a genotoxic murder mystery. <i>Molecular Cell</i> , 2002 , 10, 695-7	17.6	8
49	Wilms Tumor Suppressor WT1 2002 , 543-551		
48	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. <i>Drug Development Research</i> , 2001 , 52, 549-557	5.1	3
47	Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival. <i>Molecular and Cellular Biology</i> , 2001 , 21, 1672-81	4.8	30
46	P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. <i>Journal of Biological Chemistry</i> , 2001 , 276, 16667-73	5.4	25
45	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 10833-8	11.5	430
44	Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2001 , 353, 69-77	3.8	40
43	Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2000 , 353, 69	3.8	7
42	Role of TNF in lymphocyte-mediated cytotoxicity. <i>Microscopy Research and Technique</i> , 2000 , 50, 196-208	2.8	44
41	Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. <i>Oncogene</i> , 2000 , 19, 6033-42	9.2	88
40	Multiple physiological functions for multidrug transporter P-glycoprotein?. <i>Trends in Biochemical Sciences</i> , 2000 , 25, 1-6	10.3	270
39	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000 , 95, 2378-2385	2.2	75
38	Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis. <i>Journal of Biological Chemistry</i> , 2000 , 275, 39262-6	5.4	73
37	Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3. <i>Journal of Biological Chemistry</i> , 2000 , 275, 32052-6	5.4	62

36	Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1403-14	16.6	300
35	A role for P-glycoprotein in regulating cell death. <i>Leukemia and Lymphoma</i> , 2000 , 38, 1-11	1.9	100
34	Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 276, 231-73-4	13	
33	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000 , 95, 2378-2385	2.2	2
32	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. <i>Blood</i> , 1999 , 93, 1075-1085	2.2	273
31	Structural organization, tissue expression, and chromosomal localization of Ciao 1, a functional modulator of the Wilms tumor suppressor, WT1. <i>Immunogenetics</i> , 1999 , 49, 900-905	3.2	1
30	Transcription and growth regulatory functions of the HIN-200 family of proteins. <i>Molecular and Cellular Biology</i> , 1999 , 19, 5833-8	4.8	103
29	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. <i>Blood</i> , 1999 , 93, 1075-1085	2.2	16
28	Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. <i>Journal of Immunology</i> , 1999 , 163, 1350-3	5.3	31
27	The question begs--what is the role of P-glycoprotein in normal physiology?. <i>Drug Resistance Updates</i> , 1998 , 1, 340-2	23.2	
26	Isotypic variants of the interferon-inducible transcriptional repressor IFI 16 arise through differential mRNA splicing. <i>Biochemistry</i> , 1998 , 37, 11924-31	3.2	48
25	Mapping of the human PAWR (par-4) gene to chromosome 12q21. <i>Genomics</i> , 1998 , 53, 241-3	4.3	44
24	Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. <i>Journal of Biological Chemistry</i> , 1998 , 273, 10880-7	5.4	54
23	The human interferon-inducible protein, IFI 16, is a repressor of transcription. <i>Journal of Biological Chemistry</i> , 1998 , 273, 17172-7	5.4	58
22	The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 7024-9	11.5	299
21	The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. <i>Journal of Leukocyte Biology</i> , 1998 , 64, 546-54	6.5	31
20	Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific CD8+ cytotoxic T lymphocytes. <i>Journal of Virology</i> , 1998 , 72, 5948-54	6.6	17
19	Expression and function of the leucine zipper protein Par-4 in apoptosis. <i>Molecular and Cellular Biology</i> , 1997 , 17, 3823-32	4.8	183

18	Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. <i>Oncogene</i> , 1997 , 15, 453-7	9.2	196
17	A novel repressor, par-4, modulates transcription and growth suppression functions of the WilmsO tumor suppressor WT1. <i>Molecular and Cellular Biology</i> , 1996 , 16, 6945-56	4.8	232
16	Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. <i>Transplantation Proceedings</i> , 1994 , 26, 1070-1	1.1	6
15	Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. <i>Molecular Immunology</i> , 1993 , 30, 1231-41	4.3	82
14	Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. <i>Transplant Immunology</i> , 1993 , 1, 101-8	1.7	39
13	CD46 (MCP) confers protection from lysis by xenogeneic antibodies. <i>Transplantation Proceedings</i> , 1993 , 25, 396-7	1.1	4
12	Identification and quantification of complement regulator CD46 on normal human tissues. <i>Immunology</i> , 1993 , 79, 341-7	7.8	81
11	Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. <i>Journal of Neuroimmunology</i> , 1992 , 36, 199-208	3.5	37
10	Strong associations between RFLP and protein polymorphisms for CD46. <i>Immunogenetics</i> , 1992 , 36, 79-85	3.2	21
9	Functional characterisation of alternatively spliced CD46 cytoplasmic tails. <i>Transplantation Proceedings</i> , 1992 , 24, 2329-30	1.1	10
8	Tissue-specific expression of CD46 isoforms. <i>Transplantation Proceedings</i> , 1992 , 24, 2331-2	1.1	4
7	Molecular characterization of the polymorphic expression of CD46: a cell surface molecule protecting cells from complement attack. <i>Transplantation Proceedings</i> , 1992 , 24, 211-3	1.1	3
6	Identification of four different CD46 (MCP) molecules with anti-peptide antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 180, 1091-7	3.4	9
5	The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. <i>Molecular Immunology</i> , 1990 , 27, 327-33	4.3	52
4	Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice. <i>Cancer Research</i> , 1990 , 50, 4423-8	10.1	15
3	Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). <i>Cancer Research</i> , 1990 , 50, 5225-30	10.1	18
2	Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia		1
1	A PP2A-Integrator complex fine-tunes transcription by opposing CDK9		1

